دورية أكاديمية
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS)
| العنوان: | A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS) |
|---|---|
| المؤلفون: | Erica N. Peters, Helena Yardley, Amy Harrison, Graham M.L. Eglit, Jose Antonio, Cynthia Turcotte, Marcel O. Bonn-Miller |
| المصدر: | Journal of the International Society of Sports Nutrition, Vol 20, Iss 1 (2023) |
| بيانات النشر: | Taylor & Francis Group, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Nutrition. Foods and food supply LCC:Sports medicine |
| مصطلحات موضوعية: | Cannabidiol, cannabigerol, recovery, DOMS, delayed onset muscle soreness, Nutrition. Foods and food supply, TX341-641, Sports medicine, RC1200-1245 |
| الوصف: | ABSTRACTBackground Cannabinoid-containing products are marketed to athletes as promoting recovery, in spite of a lack of data on their safety and effects. This randomized, double-blind, placebo-controlled, repeated-dose pilot study tested the safety, tolerability, and preliminary effects on recovery of a formulation containing cannabidiol (CBD; 35 mg), cannabigerol (CBG; 50 mg), beta caryophyllene (BCP; 25 mg), branched-chain amino acids (BCAAs; 3.8 g), and magnesium citrate (420 mg).Methods Exercise-trained individuals (N = 40) underwent an experimental induction of delayed onset muscle soreness (DOMS) and completed follow-up visits 24-, 48-, and 72-hours post-DOMS. Participants were randomized to active or placebo formulation, and consumed the formulation twice per day for 3.5 days.Results There was one adverse event (AE) in the active group (diarrhea) and two AEs in placebo (dry mouth; eye rash/swollen eye). There was 100% self-reported compliance with formulation consumption across the two groups. For the primary outcome of interest, the estimate of effect for ratings of average soreness/discomfort 72 hours post-DOMS between active and placebo groups was −1.33 (85% confidence interval = -2.55, −0.10), suggesting moderate evidence of a treatment difference. The estimate of effect for the outcome of ratings of interference of soreness, discomfort, or stiffness on daily activities at work or home 48 hours post-DOMS was −1.82 (95% confidence interval = -3.64, −0.01), indicating a treatment difference of potential clinical importance. There was no significant effect between active and placebo groups on objective measures of recovery, sleep quality, or mood disturbance.Conclusions The tested formulation reduced interference of DOMS on daily activities, demonstrating its improvement on a functional aspect of recovery. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 15502783 1550-2783 |
| Relation: | https://doaj.org/toc/1550-2783 |
| DOI: | 10.1080/15502783.2023.2280113 |
| URL الوصول: | https://doaj.org/article/0955398cc3024183a7441ef4a64b844e |
| رقم الأكسشن: | edsdoj.0955398cc3024183a7441ef4a64b844e |
| قاعدة البيانات: | Directory of Open Access Journals |
PDF full text from Publisher 
Full Text Finder | تدمد: | 15502783 |
|---|---|
| DOI: | 10.1080/15502783.2023.2280113 |